Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that primary care physicians are more willing than endocrinologists to prescribe Pfizer/Nektar's Exubera. According to the new Physician & Payer Forum report entitled Reimbursement of Inhaled Insulins: Safety and Efficacy Concerns vs. Improved Patient Compliance, 54 percent of primary care physicians and 41 percent of endocrinologists say they will increase the number of prescriptions they write for insulin generally.

The report also finds that half of managed care organizations' pharmacy directors believe that inhaled insulin will promote earlier use of insulin among patients. Most managed care pharmacy directors do not perceive that inhaled insulin is worth a price premium over injectable insulin analogues. One half of managed care pharmacy directors say they would not cover inhaled insulin in their health plans on the basis of improved compliance alone.

"Greater than 90 percent of surveyed physicians say that the availability of an orally administrated insulin pill would promote earlier use of insulin," said Donny Wong, Ph.D., analyst at Decision Resources. "Development of oral insulin would create tremendous market opportunity based on this anticipated need but at present, the only non-injectable insulin available is Exubera inhaled insulin."

Reimbursement of Inhaled Insulins: Safety and Efficacy Concerns vs. Improved Patient Compliance is based on a U.S. survey of 17 MCO pharmacy directors, 71 primary care physicians, and 70 endocrinologists, and 150 patients. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic, and scientific factors.

About Physician & Payer Forum

Physician & Payer Forum is a primary research service from Decision Resources that offers access to high volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Uptake of New Therapies From Bristol-Myers Squibb/Gilead, Johnson & Johnson/Tibotec, Merck, and Pfizer Will Drive Near-Term Growth in the HIV Drug Market

View Now